Image Source: AsiaOne
Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER GlobeNewswire October 29, 2020 Q3 2020 sales growth(2) driven by strong Dupixent® and flu vaccines demand. Net sales were €9,479 million, up 5.7%(2) at CER and down 0.2% on a reported basis. Specialty Care sales grew 23.8%, driven by strong Dupixent® performance (+68.6% to €918 million) and growth in all franchises.Vaccines sales up 13.6%, driven by record flu sales partly offset by decline in boosters, travel and Menactra® due to COVID-19. General Medicines sales single-digit decline (-6.4%), reflecting China VBP program and U.S. Diabetes.CHC sales down 1.1% due to Zantac® voluntary recall in October 2019 and lower in-person pharmacy traffic in Rest of the World.Q3 2020 business EPS(1) growth at CER driven mainly by strong sales performance and efficiencies.
Source: AsiaOne